ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TSTL Tristel Plc

447.50
0.00 (0.00%)
09 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 447.50 440.00 455.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 36.01M 4.46M 0.0941 47.56 212.12M

Tristel PLC EPA approval received (6996L)

23/04/2018 7:00am

UK Regulatory


Tristel (LSE:TSTL)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Tristel Charts.

TIDMTSTL

RNS Number : 6996L

Tristel PLC

23 April 2018

Tristel plc

("Tristel" or "the Company")

EPA approval received

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that the United States Environmental Protection Agency ("EPA") has registered its foam-based chlorine dioxide product, Duo. This registration enables Tristel to market Duo to clean and disinfect hard, non-porous surfaces. The federal registration will be followed by state-by-state approvals which the Company expects to complete by the end of 2018. The Company anticipates first revenues from the United States during its 2018-19 financial year.

Paul Swinney, CEO of Tristel plc, comments: "We have achieved our first United States regulatory approval, and we will continue to pursue further registrations with the EPA and the Food and Drug Administration ("FDA") to build a broadly-based business in the USA.

"We recently announced that we have appointed Parker Laboratories Inc to manufacture Duo in its FDA approved facility in New Jersey, and to sell Duo into the ultrasound marketplace in which they have national sales coverage. We will sell our products through different channels into other clinical areas in the USA hospital market.

"This first United States approval is a very significant step for our Company as it enables us to access the largest healthcare market in the world. It has been our long-held ambition to be recognised as a global brand in the infection prevention industry. An active presence in the United States is necessary to achieve this ambition, and now we can build upon the foundation stone laid in our collaboration with Parker to progress confidently towards our goal."

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact:

 
 Tristel plc                                                  Tel: 01638 721 500 
 Paul Swinney, Chief Executive 
  Officer 
 Liz Dixon, Finance Director 
 
 Walbrook PR Ltd                    Tel: 020 7933 8780 or tristel@walbrookpr.com 
 Paul McManus                                                 Mob: 07980 541 893 
 Lianne Cawthorne                                             Mob: 07584 391 303 
 
 finnCap                                                      Tel: 020 7220 0500 
 Geoff Nash/ Giles Rolls (Corporate 
  Finance) 
 Alice Lane (Corporate Broking) 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCFKBDNQBKDPQB

(END) Dow Jones Newswires

April 23, 2018 02:00 ET (06:00 GMT)

1 Year Tristel Chart

1 Year Tristel Chart

1 Month Tristel Chart

1 Month Tristel Chart

Your Recent History

Delayed Upgrade Clock